# EDGAR Filing Document

**Accession Number:** 0001830214
**File Stem:** 0001628280-26-012364
**Filing Date:** 2026-2
**Character Count:** 38902
**Document Hash:** 52207ac1937315e68a7cabd5571c7621
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-012364.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001628280-26-012364

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**EFFECTIVENESS DATE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ginkgo Bioworks Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001830214
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 872652913
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293808
- **FILM NUMBER:** 26690022

**BUSINESS ADDRESS:**
- **STREET 1:** 27 DRYDOCK AVENUE
- **STREET 2:** 8TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (877) 442-5362

**MAIL ADDRESS:**
- **STREET 1:** 27 DRYDOCK AVENUE
- **STREET 2:** 8TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Soaring Eagle Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Spinning Eagle Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201027

**As filed with the United States Securities and Exchange Commission on February 26, 2026.** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

**GINKGO BIOWORKS HOLDINGS, INC.** 

**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **87-2652913** |
| **(State or Other Jurisdiction of**<br>**Incorporation or Organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**27 Drydock Avenue** 

**8th Floor** 

**Boston, MA 02210** 

**(877) 422-5362** 

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)** 

**Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan** 

**(Full title of the plan)** 

**Steven Coen**

**Chief Financial Officer** 

**Ginkgo Bioworks Holdings, Inc.** 

**27 Drydock Avenue** 

**8th Floor** 

**Boston, MA 02210** 

**(877) 422-5362** 

**(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)** 

***Copies to:***

------

---

| | |
|:---|:---|
| **Marko Zatylny**<br>**Ropes & Gray LLP**<br>**Prudential Tower**<br>**800 Boylston Street**<br>**Boston, MA 02199**<br>**(617) 951-7000** | **Karen Tepichin**<br>**General Counsel**<br>**Ginkgo Bioworks Holdings, Inc.**<br>**27 Drydock Avenue**<br>**8th Floor**<br>**Boston, MA 02210**<br>**(877) 422-5362** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

**REGISTRATION OF ADDITIONAL SHARES**

**PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E of Form S-8, the Ginkgo Bioworks Holdings, Inc. (the "Company") is filing this Registration Statement with the Securities and Exchange Commission (the "Commission") to register (1) 2,467,217 additional shares of the Company's Class A common stock, $0.0001 par value per share (the "Class A Common Stock") and 2,467,217 additional shares of the Company's Class B common stock, $0.0001 par value per share (the "Class B Common Stock") under the Company's 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), pursuant to the provision of the plan providing for an automatic increase in the number of shares reserved for issuance under such plan for the 2026 fiscal year, and subject to the share limits prescribed in such plan. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis). As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.

This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statements on Form S-8 filed with the Commission on February 25, 2025 (Registration No. 333-285235), March 1, 2024 (Registration No. 333-277558), March 13, 2023 (Registration No. 333-270506), October 19, 2022 (Registration No. 333-267952) and November 19, 2021 (Registration No. 333-261205).

**PART II** 

------

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.** |

---

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of Ginkgo Bioworks Holdings, Inc. (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on August 19, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001830214/000162828024037685/dna-20240819.htm)</u> |
| 4.2 | <u>[Amended and Restated Bylaws of Ginkgo Bioworks Holdings, Inc. (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on October 27, 2023).](https://www.sec.gov/Archives/edgar/data/1830214/000119312523265256/d563263dex31.htm)</u> |
| 4.3 | <u>[Specimen Class A Common Stock Certificate of Ginkgo Bioworks Holdings, Inc. (incorporated by reference to Exhibit 4.5 to Amendment No. 3 to the Registration Statement on Form S-4 (File No. 333-256121) filed with the SEC on August 4, 2021).](https://www.sec.gov/Archives/edgar/data/1830214/000119312521235409/d177007dex45.htm)</u> |
| 4.4 | <u>[Form of Ginkgo Bioworks Holdings, Inc. 2021 Award Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company's Annual Report on Form 10-K filed with the SEC on February 25, 2025).](https://www.sec.gov/Archives/edgar/data/1830214/000162828025007819/dna-20241231xex101.htm)</u> |
| 5.1\* | <u>[Opinion of Ropes & Gray LLP.](ginkgos-8x51opinion2025eve.htm)</u> |
| 23.1\* | <u>[Consent of Deloitte & Touche LLP, independent registered public accounting firm of Ginkgo Bioworks Holdings, Inc.](deloitteconsent-sx8.htm)</u>  |
| 23.2\* | <u>[Consent of Ernst & Young LLP, independent registered public accounting firm of Ginkgo Bioworks Holdings, Inc.](eyconsent-sx8.htm)</u>  |
| 23.3\* | <u>[Consent of Ropes & Gray LLP (included in Exhibit 5.1 to this Registration Statement).](ginkgos-8x51opinion2025eve.htm)</u> |
| 24.1\* | <u>[Power of Attorney (included on the signature page to this Registration Statement).](#i917e373eb148457884a007c300d5173e_5757)</u> |
| 107\* | <u>[Filing Fee Table](ginkgo-sx8filingfeetable20.htm)</u> |

---

\* Filed herewith.

**SIGNATURES** 

------

Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on February 26, 2026.

---

| |
|:---|
| Ginkgo Bioworks Holdings, Inc. |
| <u>/s/ Jason Kelly</u> |
| Name: Jason Kelly |
| Title: Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Jason Kelly and Steven Coen, acting alone or with another attorney-in-fact, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Registration Statement on Form S-8 of Ginkgo Bioworks Holdings, Inc. and any subsequent registration statements related thereto pursuant to Instruction E to Form S-8 (and all further amendments, including post-effective amendments thereto), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the "SEC"), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the Company to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated.

------

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| <u>/s/ Jason Kelly</u> | Chief Executive Officer and Director | February 26, 2026 |
| **Jason Kelly** | (Principal Executive Officer) |  |
| <u>/s/ Steven Coen</u> | Chief Financial Officer | February 26, 2026 |
| **Steven Coen** | (Principal Financial Officer and<br>Principal Accounting Officer) |  |
| <u>/s/ Shyam Sankar</u> | Director, Chair of the Board | February 26, 2026 |
| **Shyam Sankar** |  |  |
| <u>/s/ Ross Fubini</u> | Director | February 26, 2026 |
| **Ross Fubini** |  |  |
| **<u>/</u>**<u>s</u>**<u>/</u>** <u>Christian Henry</u> | Director | February 26, 2026 |
| **Christian Henry** |  |  |
| <u>/s/ Sri Kosuri</u> | Director | February 26, 2026 |
| **Sri Kosuri** |  |  |
| <u>/s/ Reshma Shetty</u> | President and Director | February 26, 2026 |
| **Reshma Shetty** |  |  |
| <u>/s/ Harry E. Sloan</u> | Director | February 26, 2026 |
| **Harry E. Sloan** |  |  |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Ginkgo Bioworks Holdings, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Share** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Equity | Class A common stock, par value $0.0001 per share | 457(c) and 457(h) | 2467217 <sup>(2)</sup> | $9.40 <sup>(3)</sup> | $23191839.80 <sup>(3)</sup> | 0.00013810 | $3202.79 <sup>(3)</sup> |
| Equity | Equity | Class B common stock, par value $0.0001 per share | 457(c) and 457(h) | 2467217 <sup>(2)</sup> | $9.40 <sup>(3)</sup> | $23191839.80 <sup>(3)</sup> | 0.00013810 | $0 <sup>(4)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** |  | $23191839.80 |  | $3202.79 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** |  |  |  | $0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** |  |  |  | $3202.79 |
| <br>(1) | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  | <br>Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), and Class B common stock, par value $0.0001 per share (the "Class B Common Stock", together with the Class A Common Stock, the "Common Stock"), of Ginkgo Bioworks Holdings, Inc. (the "Company") that become issuable under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (the "2021 Incentive Award Plan"), by reason of any future share splits, share dividends, recapitalizations or any other similar transactions effected without the receipt of consideration by the Company, which results in an increase in the number of outstanding shares of Class A Common Stock or Class B Common Stock. The shares authorized for issuance under the 2021 Incentive Award Plan can be either in the form of Class A Common Stock (that is convertible to Class B Common Stock on a one-for-one basis) or Class B Common Stock (that is convertible to Class A Common Stock on a one-for-one basis), as determined by the Company. As a result, we have registered the maximum number of shares of Class A Common Stock and the maximum number of shares of Class B Common Stock that could be issued.  |
| (2) | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  | Represents 2,467,217 additional shares of each of Class A Common Stock and Class B Common Stock reserved for future issuance under the 2021 Incentive Award Plan resulting from the annual "evergreen" increase in the number of authorized shares of Class A Common Stock and Class B Common Stock reserved and available for issuance for the 2026 fiscal year under the 2021 Incentive Award Plan on January 1 of each of 2022 through 2031. The annual increase of each of the Class A Common Stock and Class B Common Stock is equal to the lesser of (a) 4% of the number of shares of the Company's common stock issued and outstanding on each December 31 immediately prior to the date of increase and (b) such number of shares determined by the Company's board of directors.  |
| (3) | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Company's common stock on the New York Stock Exchange on February 20, 2026. |
| (4) | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. | The Company has only paid a registration fee for 2,467,217 shares (the aggregate number of additional shares of Class A Common Stock and Class B Common Stock authorized for issuance pursuant to the 2021 Incentive Award Plan's "evergreen" provision). For purposes of clarity, no more than an additional 2,467,217 shares of any class will be issued under the Plan with respect to new awards pursuant to this Registration Statement. |

---

## Exhibit 5.1

ROPES & GRAY LLPPRUDENTIAL TOWER800 BOYLSTON STREETBOSTON, MA 02199-3600WWW.ROPESGRAY.COM

**Exhibit 5.1**

February 26, 2026

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed by Ginkgo Bioworks Holdings, Inc., a Delaware corporation (the "<u>Company</u>"), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of (i) 2,467,217 shares of the Company's Class A common stock, $0.0001 par value per share, and 2,467,217 shares of the Company's Class B common stock, $0.0001 par value per share, issuable pursuant to the Company's 2021 Incentive Award Plan (the "<u>Plan</u>"). The shares issuable under the Plan for registration on the Registration Statement are referred to collectively as the "<u>Shares</u>."

We are familiar with the actions taken by the Company in connection with the adoption of the Plan. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plan, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 26, 2026 relating to the financial statements of Ginkgo Bioworks Holdings, Inc. and the effectiveness of Ginkgo Bioworks Holdings, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Ginkgo Bioworks Holdings, Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

February 26, 2026

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2021 Incentive Award Plan of Ginkgo Bioworks Holdings, Inc. of our report dated February 29, 2024 (except for note 16 and the effects of the reverse stock split as described in note 2, as to which the date is February 25, 2025) with respect to the consolidated financial statements of Ginkgo Bioworks Holdings, Inc. included in its Annual Report (Form 10-K), filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

February 26, 2026

<br>